North American Cannabis Holdings, Inc. (USOTC: USMJ) (“USMJ”) today announced publishing its quarterly financial report for the period ending December 31, 2018. The company reported $233,000 in revenue for the quarter with a net profit of $18,500. Revenue is approximately 8% higher than reported for the same period in the prior year. USMJ recently launched its all new eCommerce site for CBD products and other cannabis essentials at WWW.USMJ.COM. Management anticipates the new eCommerce site to produce the majority of the company’s revenue and growth moving forward. The current financial report does not include any benefit yet from the new eCommerce site. USMJ plans to continue expanding the number and variety of products available from WWW.USMJ.COM. The site includes EVERx CBD Sports Water from USMJ’s sister company, Puration Inc. (USOTC: PURA). Kali-Extracts’ (USOTC: KALY) Hemp4mula CBD infused gum and gummies will soon be on the site in addition to Kali-Extracts own line of CBD oils. The 2019 Miss USMJ Calendar is also available at WWW.USMJ.COM. Cannabis essentials and CBD products from other specialty manufactures can also be found at WWW.USMJ.COM and USMJ plans to also continue expanding the number and variety of cannabis themed products from other specialty manufactures. USMJ’s plans for WWW.USMJ.COM are to brand the site as an essential resource for people that identify as members of the cannabis community. USMJ and the Miss USMJ Team will be soon launching a series of pop-up cannabis community events as part of the strategy to brand WWW.USMJ.COM.
USMJ management plans to publish a shareholder update later this week with the latest on the pending dividend of PJET stock to USMJ shareholders in addition to the latest operational developments with companies new eCommerce site.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.